SE9700617D0 - New composition - Google Patents

New composition

Info

Publication number
SE9700617D0
SE9700617D0 SE9700617A SE9700617A SE9700617D0 SE 9700617 D0 SE9700617 D0 SE 9700617D0 SE 9700617 A SE9700617 A SE 9700617A SE 9700617 A SE9700617 A SE 9700617A SE 9700617 D0 SE9700617 D0 SE 9700617D0
Authority
SE
Sweden
Prior art keywords
composition
pharmaceutical composition
new composition
lozenge
urine
Prior art date
Application number
SE9700617A
Other languages
Swedish (sv)
Inventor
Kjell Alving
Eddie Weitzberg
Jan M Lundberg
Peter Wiklund
Jon Lundberg
Original Assignee
Kjell Alving
Eddie Weitzberg
Jan M Lundberg
Peter Wiklund
Jon Lundberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kjell Alving, Eddie Weitzberg, Jan M Lundberg, Peter Wiklund, Jon Lundberg filed Critical Kjell Alving
Priority to SE9700617A priority Critical patent/SE9700617D0/en
Publication of SE9700617D0 publication Critical patent/SE9700617D0/en
Priority to PCT/SE1998/000301 priority patent/WO1998047495A1/en
Priority to AU61283/98A priority patent/AU6128398A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Prevention and/or treatment of bacterial infections is achieved through the administration of a pharmaceutical composition which includes and/or enhances the formation of NO in body fluids, such as urine and vaginal secretions. Said composition comprises at least one pharmaceutically suitable acidifying agent and a reduction agent. Preferably said composition further comprises a source of nitrate. The pharmaceutical composition can be administered e.g. in the form of a lozenge, an effervescent tablet to be dissolved in water, a solution etc.
SE9700617A 1997-02-21 1997-02-21 New composition SE9700617D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE9700617A SE9700617D0 (en) 1997-02-21 1997-02-21 New composition
PCT/SE1998/000301 WO1998047495A1 (en) 1997-02-21 1998-02-20 New composition
AU61283/98A AU6128398A (en) 1997-02-21 1998-02-20 New composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9700617A SE9700617D0 (en) 1997-02-21 1997-02-21 New composition

Publications (1)

Publication Number Publication Date
SE9700617D0 true SE9700617D0 (en) 1997-02-21

Family

ID=20405878

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9700617A SE9700617D0 (en) 1997-02-21 1997-02-21 New composition

Country Status (3)

Country Link
AU (1) AU6128398A (en)
SE (1) SE9700617D0 (en)
WO (1) WO1998047495A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
CA2415397C (en) * 2000-07-11 2011-04-26 Bayer Aktiengesellschaft Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer
GB0021317D0 (en) 2000-08-30 2000-10-18 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2047878A1 (en) * 1969-06-13 1971-03-19 Chanteaud Laboratoires Treatment of pheasants using arginine, - ascorbic acid and mineral salts
FR2459047A1 (en) * 1979-06-19 1981-01-09 Begouen Jean Paul VETERINARY NITRATE MEDICINE FOR THE TREATMENT OF YOUNG CALVES DIARRHEA
CH629100A5 (en) * 1979-09-27 1982-04-15 Solco Basel Ag Hautpraeparat.
NL8401782A (en) * 1984-06-04 1986-01-02 Jan Willem Bins THERAPEUTIC PREPARATION WITH AMMONIUM NITRATE AS AN ACTIVE SUBSTANCE.
DD281543A5 (en) * 1988-06-17 1990-08-15 Univ Leipzig METHOD OF MANUFACTURING A MEANS FOR IMPROVING MUSCULAR AEROBIC PERFORMANCE, ESPECIALLY IN TRAINING AND COMPETITION EXPOSURES
DK0746327T3 (en) * 1994-02-21 2004-05-10 Univ Aberdeen Acidified nitrite as an antimicrobial agent

Also Published As

Publication number Publication date
AU6128398A (en) 1998-11-13
WO1998047495A1 (en) 1998-10-29

Similar Documents

Publication Publication Date Title
DE69826644D1 (en) TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING A CHOLINERGIC ACTIVE SUBSTANCE OR A CALCIUM CHANNEL BLOCKER
DE60125217D1 (en) TRANSDERMALE PHARMACEUTICAL COMPOSITION FOR THE ADMINISTRATIVE ADMINISTRATION
SE8903914D0 (en) ORAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
EP1243267A3 (en) Amoxycillin and clavulanate containing pharmaceutical formulation
PT1079806E (en) PREPARATIONS FOR THE APPLICATION OF ANTI-INFLAMMATORY, ESPECIALLY, ANTI-SEPTIC AGENTS AND / OR WOUND HEALING PROMOTION AGENTS, IN THE SUPERIOR AND / OR HEARING RESPIRATORY TRACT
CO4970819A1 (en) TREATMENT OF FEMALE SEXUAL DYSFUNCTION IN A HUMAN FEMALE
AR015744A1 (en) USE OF DEXMEDETOMIDINE FOR SEDATION IN INTENSIVE THERAPY
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
ES2125696T3 (en) USE OF TROPSY CHLORIDE FOR THE PRODUCTION OF A PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF VESIC DYSFUNCTIONS.
EP0848948A4 (en) Long-lasting composition for rectal administration
AR035946A1 (en) PHARMACEUTICAL COMPOSITIONS TO USE IN THE TREATMENT OF DISORDERS IN WOMEN PERIMENOPAUSIC, MENOPAUSIC OR POSMENOPAUSIC, AND USES OF SUCH COMPOSITIONS FOR THE PREPARATION OF MEDICINES
FR2784897B1 (en) USE OF AN UNFERMENTED OSMOTIC LAXATIVE IN THE TREATMENT AND PREVENTION OF COLORECTAL CANCERS
SE9700617D0 (en) New composition
KR900005974A (en) Sexual Dysfunction in Men
BR0008385A (en) Effervescent laxatives
HUP0302984A2 (en) Utilization of buprenorphine for preparation of pharmaceutical composition useful in urinary incontinence therapy
DK0927031T3 (en) Pharmaceutical composition containing nimesulide for oral administration
DE60130253D1 (en) COMPOSITIONS FOR PREVENTING ADHESION
KR960003718A (en) Use of Ifenprodil and its Diastereomers for the Preparation of Medicines Useful for the Treatment of Peripheral and Central Neurodegenerative Diseases
WO2001041771A3 (en) Transdermal system containing acetylsalicylic acid for treatment of migraine
AU2001295839A1 (en) Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa
ES2189639A1 (en) Aqueous medicinal composition containing dissolved acid consists of an oral medicine containing acetyl salicylic acid dissolved in water, with additives
WO2001028566B1 (en) Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia
RU2000103385A (en) METHOD FOR TREATING ACUTE PANCREOTITIS
UA30359A (en) The method for treatment of purulent wounds